FAQ
$ man faq
Short answers to the questions readers most often arrive with. Direct, cited, and updated through the January 2025 FDA interim 503A policy.
What is sermorelin and what is it derived from?
Sermorelin is the synthetic 29-residue C-terminally amidated fragment of human growth hormone-releasing hormone — written chemically as hGRF(1-29)NH2 [3]. Native GHRH is a 44-amino-acid hypothalamic peptide. The first 29 amino acids retain essentially full biological activity at the pituitary GHRH receptor, which is why the (1-29) fragment became the clinical compound [3]. The molecular formula is C149H246N44O42S; the molecular weight is 3357.93 Da. Sermorelin is the only true GHRH agonist in this analog family that received FDA finished-drug approval [1].
How does sermorelin work in the body?
Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs and triggers a Gs / adenylyl cyclase / cAMP / PKA second-messenger cascade [3][10]. The cascade stimulates GH gene transcription and releases pre-formed GH from secretory vesicles. The released GH then drives hepatic IGF-1 synthesis through the GH receptor's JAK2-STAT5 axis [3]. Because the pituitary remains the GH source, somatostatin and IGF-1 negative feedback stay intact — sermorelin cannot push GH past the physiological ceiling in the way exogenous recombinant GH can [3][10][12].
What is the half-life of sermorelin?
Approximately 11-12 minutes in plasma after either subcutaneous or intravenous administration [10]. Peak plasma concentration is reached 5-20 minutes after a 2 mg subcutaneous dose, and less than 5% of the dose remains detectable in plasma by 60 minutes [10]. Adult clearance is 2.4-2.8 L/min [10]. Despite the short circulating half-life, the GHRHR-mediated GH pulse it triggers persists for 2-4 hours after a single injection — the peptide is consumed quickly, but its downstream signal lasts much longer [10].
What was the original FDA-approved sermorelin and why was it discontinued?
Sermorelin acetate received two FDA approvals: a 0.05 mg diagnostic injection under NDA 19-863 in 1990, and 0.5 mg and 1.0 mg therapeutic vials under NDA 20-443 in 1997, the latter indicated for the treatment of idiopathic growth hormone deficiency and growth failure in children [1]. The sponsor submitted requests to withdraw both formulations in 2008 (the diagnostic ampule on July 11, 2008 and the therapeutic vials on December 2, 2008) [2]. The FDA published a formal determination in the March 4, 2013 Federal Register that the withdrawals were for commercial reasons and not for reasons of safety or effectiveness [2]. That preservation of the safety/efficacy record is what historically supported continued pharmacy compounding of sermorelin under Section 503A of the Federal Food, Drug, and Cosmetic Act [16].
Is sermorelin still legal in the United States in 2025?
No FDA-approved finished-drug sermorelin product is currently marketed in the United States. The original formulations were withdrawn in 2008 [2]. Sermorelin acetate is currently prepared under 503A patient-specific compounding by state-licensed pharmacists and 503B outsourcing facility manufacturing, in both cases under physician prescription [16]. The October 29, 2024 FDA Pharmacy Compounding Advisory Committee briefing materials reviewed the broader GH-secretagogue peptide class and articulated the regulatory framework under which sermorelin — by virtue of its preserved approval record — remains compoundable while several related research peptides did not advance to the 503A bulks list [17]. The January 7, 2025 FDA interim policy on 503A bulk drug substances maintains sermorelin's pathway under existing pharmacy law [16]. Compounded preparations are not reviewed by FDA for safety, efficacy, or quality before patient use [16].
How is sermorelin different from CJC-1295 and tesamorelin?
All three are GHRH receptor agonists. The principal difference is half-life [19]. Sermorelin: plasma t1/2 ~12 minutes [10]. Tesamorelin: plasma t1/2 ~26 minutes after subcutaneous dosing [19]. CJC-1295 with DAC (drug affinity complex): plasma t1/2 of several days, achieved through covalent bioconjugation to albumin [19]. Sermorelin's short half-life produces a discrete physiological GH pulse that closely mimics endogenous pulsatile release. Tesamorelin's modestly longer half-life is still pulsatile but with a broader peak. CJC-1295 with DAC produces a sustained elevation profile rather than a pulse — pharmacologically a different mode of GHRHR engagement [19]. Regulatory status also differs: sermorelin and tesamorelin both have FDA approval histories (tesamorelin remains marketed for HIV-associated lipodystrophy); CJC-1295 has no FDA-approved finished drug product.
Why is sermorelin often paired with ipamorelin in research protocols?
Co-administration of a GHRH analog with a GHS-R1a (ghrelin-receptor) agonist produces a synergistic — not merely additive — GH secretory response, several-fold greater than either agent alone [9]. The two receptors signal through distinct second-messenger pathways (cAMP/PKA for GHRHR; phospholipase C / IP3 / calcium for GHS-R1a) but converge on the same somatotroph cell. Combined activation generates a GH peak that is multiplicative rather than additive [9]. Foundational human work used GHRP-6 with GHRH [9]; modern research and compounding protocols typically substitute the selective pentapeptide ipamorelin, which delivers the GH-releasing synergy without the cortisol or prolactin elevation associated with earlier GHRPs.
What did the original pediatric trials show?
Once-daily subcutaneous sermorelin at 30 μg/kg administered at bedtime produced significant, sustained increases in height velocity in prepubertal children with idiopathic growth hormone deficiency [3]. The velocity gain was maintained through 12 months of treatment and reported through 36 months in extension cohorts. Slow-growing, shorter children with delayed bone age responded best [3]. A parallel trial in children with idiopathic short stature (not classified as GH-insufficient) used 20 μg/kg subcutaneously twice daily for 12 months — height velocity rose throughout treatment and returned to pretreatment values after cessation, confirming GHRH-axis dependence [5]. Earlier mechanistic work demonstrated that continuous subcutaneous infusion of GHRH(1-29) also promotes growth in GH-deficient children, but compared with intermittent injection showed that pulsatile stimulation patterns are required for optimal somatotropic activation [8].
What did the older-adult studies find?
Two studies dominate the published older-adult record. Khorram et al. 1997: 10 μg/kg subcutaneously nightly for 16 weeks in adults aged 55-71. Significant increases in skin thickness in both sexes, +1.26 kg lean body mass in men, improved insulin sensitivity, and self-reported gains in well-being and libido in men [6]. Vittone et al. 1997: 2 mg fixed-dose subcutaneously nightly for 6 weeks in healthy elderly men aged 64-76. IGF-1 elevation was evident by 2 weeks and sustained through 12 weeks; lean body mass increased in the longer-treated subgroup; the regimen was well tolerated [7]. Both trials were short — 6 and 16 weeks respectively. The aging dataset is not the FDA-approval dataset; the approved indication remained pediatric GHD throughout the drug's market life [1].
What are the documented side effects of sermorelin in clinical trials?
Adverse events were predominantly mild and local: transient facial flushing, redness or pain or swelling at the injection site, occasional headache, dizziness, and nausea [12]. Serious adverse events were rare across the pediatric and adult trials supporting FDA approval [12]. The safety record was preserved when the product was withdrawn for commercial reasons in 2008 — the 2013 FDA determination explicitly affirmed the withdrawal was not for safety or efficacy concerns [2]. Long-term (multi-year) safety of off-label sermorelin use in healthy aging adults has not been characterized in controlled trials. Theoretical concerns about sustained IGF-1 elevation — insulin resistance, edema, joint discomfort, neoplasia signaling — remain unresolved by the existing dataset.
Is sermorelin prohibited for athletes?
Yes. The 2025 World Anti-Doping Code Prohibited List continues to list sermorelin under Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — prohibited at all times (in-competition and out-of-competition) for any athlete subject to the WADA Code [13]. Validated nano-LC Orbitrap mass-spectrometric methods detect sermorelin and related GHRH analogs in athlete urine at sub-ng/mL concentrations [18]. The 2024 method paper addressed the analytical challenges of low urinary peptide concentration and freeze-thaw instability and is now deployed routinely in doping control [18]. Use without a granted Therapeutic Use Exemption constitutes an Anti-Doping Rule Violation [13].
Where can researchers find published information about sermorelin online?
The primary sources are PubMed and PMC for the peer-reviewed clinical literature, the FDA Federal Register for the NDA and withdrawal documentation [1][2], the FDA Pharmacy Compounding Advisory Committee briefing materials and meeting transcripts for current regulatory positioning [17], and the WADA website for the current Prohibited List [13]. The references page on this site links to all 19 cited sources with DOIs and direct URLs. The Prakash & Goa 1999 BioDrugs review and the Ishida et al. 2020 JCSM growth-hormone-secretagogues review are useful narrative entry points to the full historical literature [3][19].
Does sermorelin make you grow taller as an adult?
No. The growth-velocity studies were in prepubertal children with open growth plates [3][5][8]. Once growth plates fuse at the end of puberty, GH and IGF-1 elevation cannot increase linear stature. The aging-population studies in adults reported body-composition and skin-thickness changes — not height changes [6][7].
Can sermorelin work if the pituitary is damaged?
Sermorelin cannot fully restore GH levels in patients whose pituitary somatotrophs are functionally absent — for example after pituitary tumor resection, after radiation therapy involving the sella, or in congenital somatotroph aplasia. The secretagogue mechanism requires an intact pituitary capable of producing and storing GH. This is one of the reasons recombinant human growth hormone — which supplies the hormone directly — supplanted sermorelin for most pediatric GHD treatment after the 2008 withdrawal.